Sitewide
Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index.
Popular Today:
Similar Articles On This Topic:
- Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
- Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
- Celiac disease vaccine shows promising results in Phase I trial
- First trial of gene therapy for advanced heart failure shows promising results
- Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
Science 2.0:
- Thank Climate Change For Early Human Technological Innovation
- Pregnancy: Moderate Drinking Doesn't Harm Baby's Neurodevelopment
- Consumer Research: It's Easier To Lose Weight When The Target Is Not Exact
- Smoking Linked To Adverse Neurosurgical Outcomes
- Determinism: Baby's Weight Gain In First Month Linked To IQ
Recent Articles:
Create Your Own Releases:
Post new comment